Automatic positive electron radioactive medicine synthesis module based on 18F-BF3 markers

Abstract

The invention discloses an automatic positive electron radioactive medicine synthesis module based on 18F-BF3 markers and belongs to the fields of nuclear medicines and molecular imaging. The synthesis module comprises a 18F-ion adsorption, purification and leaching system, a heating reaction system, a synthesis purification system and a product sterilization treatment and transfer system, whereinthe 18F-ion adsorption, purification and leaching system and the synthesis purification system are respectively connected with the heating reaction system through pipelines; the product sterilizationtreatment and transfer system is connected with the synthesis purification system through a pipeline; the 18F-ion adsorption, purification and leaching system is capable of achieving precise weighingand nondestructive transferring of 18F-ion leacheate of a micro volume through an injection pump Z2, a two-position six-way proportional valve F2 and a quantitative loop. Compared with the prior art,the automatic synthesis module has the characteristics of being novel in design, stable in performance, flexible to use, convenient to maintain, easy to popularize, and the like, and is particularlyapplicable to synthesis of polypeptide positive electron medicines based on 18F-BF3 marker strategies in an aqueous environment.

Description

technical field [0001] The invention relates to the fields of nuclear medicine and molecular imaging, in particular to an automatic synthesis module of positron radiopharmaceuticals based on 18F-BF3 labeling. Background technique [0002] At present, the most widely used PET positron drug in clinical practice is 18F-FDG, but this imaging agent can only observe the abnormal glucose metabolism of tumors, and there are certain problems in specificity (it cannot effectively distinguish between inflammation and tumor tissue). It is also not suitable for brain imaging. In order to make up for these shortcomings, many imaging agents with different targets have come out one after another, such as 18F-FLT based on proliferation imaging, 18F-FMISO for hypoxia imaging, and amino acid metabolism. 18F-ethyltyrosine, etc., and these imaging agents can utilize commercialized full-automatic synthesizers (such as Tracer LabFX F-N series of General Electric Company (Medical Systems) of the Un...

AI Technical Summary

Problems solved by technology

However, this 18F labeling strategy has the following problems: 1. The labeling process is cumbersome and takes a long time; 2. Two-step labeling, the overall labeling yield is low; 3. The target probe must be purified by HPLC to effectively Molecular separation is time-consuming and labor-intensive

In the current situation of increased demand for medication, manual operations not only increase the occupational exposure of staff, but also increase the risk of human error in the pharmaceutical process

However, the existing commercialized multifunctional automatic synthesizers can only be used for the preparation of limited types of 18F positron drugs, and the current commercialized module liquid transfer scheme mainly uses nitrogen positive pressure to transfer the liquid in the reagent bottle, which cannot achieve micro-volume Precise measurement and non-destructive transfer, so it is not suitable for the preparation of this new 18F-BF3 positron drug

Images